NO20016380L - Fremgangsmåte for å forhindre tumorvekst - Google Patents

Fremgangsmåte for å forhindre tumorvekst

Info

Publication number
NO20016380L
NO20016380L NO20016380A NO20016380A NO20016380L NO 20016380 L NO20016380 L NO 20016380L NO 20016380 A NO20016380 A NO 20016380A NO 20016380 A NO20016380 A NO 20016380A NO 20016380 L NO20016380 L NO 20016380L
Authority
NO
Norway
Prior art keywords
tumor growth
procedure
preventing tumor
preventing
ltbr
Prior art date
Application number
NO20016380A
Other languages
English (en)
Other versions
NO20016380D0 (no
Inventor
Daniela N Maennel
Thomas Hehlgans
Carola Seitz
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999129488 external-priority patent/DE19929488A1/de
Priority claimed from DE2000104447 external-priority patent/DE10004447A1/de
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20016380L publication Critical patent/NO20016380L/no
Publication of NO20016380D0 publication Critical patent/NO20016380D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Fremgangsmåte for forhindring av betennelser, autoimmune sykdommer og tumorvekst ved å undertrykke LTBR-mediert aktivering, beskrives.
NO20016380A 1999-06-28 2001-12-27 Fremgangsmåte for å forhindre tumorvekst NO20016380D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999129488 DE19929488A1 (de) 1999-06-28 1999-06-28 Verfahren zur Verhinderung von Tumorwachstum
DE2000104447 DE10004447A1 (de) 2000-02-03 2000-02-03 Verfahren zur Verhinderung von Tumorwachstum
PCT/EP2000/005738 WO2001000228A1 (de) 1999-06-28 2000-06-21 Verfahren zur verhinderung von tumorwachstum

Publications (2)

Publication Number Publication Date
NO20016380L true NO20016380L (no) 2001-12-27
NO20016380D0 NO20016380D0 (no) 2001-12-27

Family

ID=26004148

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016380A NO20016380D0 (no) 1999-06-28 2001-12-27 Fremgangsmåte for å forhindre tumorvekst

Country Status (20)

Country Link
EP (1) EP1189626B1 (no)
JP (1) JP3822822B2 (no)
KR (1) KR20020016852A (no)
CN (1) CN1359297A (no)
AT (1) ATE410180T1 (no)
AU (1) AU5406000A (no)
BG (1) BG106246A (no)
BR (1) BR0012006A (no)
CA (1) CA2376920A1 (no)
DE (1) DE50015391D1 (no)
ES (1) ES2313893T3 (no)
HK (1) HK1047045A1 (no)
HU (1) HUP0201804A2 (no)
IL (1) IL147180A0 (no)
MX (1) MXPA01013367A (no)
NO (1) NO20016380D0 (no)
PL (1) PL353057A1 (no)
SK (1) SK18852001A3 (no)
TR (1) TR200103841T2 (no)
WO (1) WO2001000228A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134994A0 (en) 2000-03-09 2001-05-20 Yeda Res & Dev Coupled two way clustering analysis of data
AU2003292696A1 (en) 2002-12-26 2004-08-10 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
RU2006145886A (ru) 2004-06-25 2008-06-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные метастина и их применение
WO2007041694A2 (en) * 2005-10-04 2007-04-12 The Johns Hopkins University Compositions and methods for treating inflammation
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
WO2008083169A2 (en) * 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
AU726357B2 (en) * 1996-10-25 2000-11-02 Biogen Idec Ma Inc. Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
CN1287853C (zh) * 1998-01-30 2006-12-06 拜奥根Idec马萨诸塞公司 用淋巴毒素(lt)途径抑制物治疗滤泡性淋巴瘤

Also Published As

Publication number Publication date
NO20016380D0 (no) 2001-12-27
JP2003503359A (ja) 2003-01-28
PL353057A1 (en) 2003-10-06
KR20020016852A (ko) 2002-03-06
ES2313893T3 (es) 2009-03-16
CA2376920A1 (en) 2001-01-04
MXPA01013367A (es) 2002-07-02
AU5406000A (en) 2001-01-31
ATE410180T1 (de) 2008-10-15
JP3822822B2 (ja) 2006-09-20
TR200103841T2 (tr) 2002-06-21
EP1189626B1 (de) 2008-10-08
WO2001000228A1 (de) 2001-01-04
BG106246A (en) 2002-10-31
DE50015391D1 (de) 2008-11-20
SK18852001A3 (sk) 2002-12-03
HUP0201804A2 (en) 2002-09-28
EP1189626A1 (de) 2002-03-27
HK1047045A1 (zh) 2003-02-07
IL147180A0 (en) 2002-08-14
CN1359297A (zh) 2002-07-17
BR0012006A (pt) 2002-03-12

Similar Documents

Publication Publication Date Title
CA2388646A1 (en) Methods and compositions utilizing quinazolinones
MY140767A (en) Compounds, methods and compositions
WO2003103575A3 (en) COMPOUNDS, COMPOSITIONS AND METHODS
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
TR199802676A3 (tr) Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem.
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
WO2003088903A3 (en) Compounds, compositions, and methods
AU2079901A (en) Thrombopoietin mimetics
WO2004009036A3 (en) Compounds compositions and methods
EA200001129A2 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
HK1040983A1 (en) Quinones for treatment of diseases.
AU2003252025A1 (en) Compounds, compositions, and methods
NO20016380L (no) Fremgangsmåte for å forhindre tumorvekst
AU7847800A (en) Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
WO2001035995A3 (en) Tr3-specific binding agents and methods for their use
WO2004032879A3 (en) Compounds, compositions, and methods
WO2001056593A3 (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
ZA200203166B (en) Treatment of cancer.
AU2607999A (en) Sustained release implant, methods for preparation thereof and for treating cancer
AU2202301A (en) Cd45 inhibitors
AU6234000A (en) Methods for treating autoimmune diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application